Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
...
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1191
- Registration Number
- NCT00765674
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke (0954-338)(COMPLETED)
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2013-10-23
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 40
- Registration Number
- NCT00754429
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT00700271
- Locations
- 🇹🇳
Investigative sites in Tunisia, Tunisia, Tunisia
🇫🇷Investigative sites in France, Paris, France
Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 965
- Registration Number
- NCT00699192
- Locations
- 🇮🇹
Investigative site Italy, Rome, Italy
🇨🇿Investigative sites Czech Republic, Praha, Czech Republic
🇸🇪Investigative site Sweden, Malmo, Sweden
Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2008-08-08
- Lead Sponsor
- Anhui Medical University
- Target Recruit Count
- 360
- Registration Number
- NCT00693199
- Locations
- 🇨🇳
Biomedicine Inistitute of Anhui Medical University, Hefei, Anhui, China
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 564
- Registration Number
- NCT00667719
- Locations
- 🇹🇷
Investigative Site, Turkey, Turkey
Black Education and Treatment of Hypertension (BEAT HTN)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 99
- Registration Number
- NCT00661895
- Locations
- 🇺🇸
Creighton Community Health Center, Omaha, Nebraska, United States
Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2008-04-16
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 100
- Registration Number
- NCT00659451
- Locations
- 🇮🇹
University of Pavia, Pavia, Italy
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2010-07-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 207
- Registration Number
- NCT00654745
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2500
- Registration Number
- NCT00649389
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.